Leukocyte Patents (Class 424/93.71)
  • Patent number: 10266805
    Abstract: Human progenitor T cells that are able to successfully engraft a murine thymus and differentiate into mature human T and NK cells are described. The human progenitor T cells have the phenotype CD34+CD7+CD 1a?CD5? or CD34+CD7+CD1a?CD5+ and are derived from human hematopoietic stem cells, embryonic stem cells and induced pluripotent stem cells by coculture with cells expressing a Notch receptor ligand (OP9-DL1 or OP9-DL4). Such cells are useful in a variety of applications including immune reconstitution, the treatment of immunodeficiencies and as carriers for genes used in gene therapy.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: April 23, 2019
    Assignee: Sunnybrook Health Sciences Centre
    Inventors: Juan Carlos Zuniga-Pflucker, Geneve Awong, Ross La Motte-Mohs
  • Patent number: 10195231
    Abstract: Modified natural killer cells, pharmaceutical compositions comprising the modified natural killer cells and at least one pharmaceutically acceptable carrier or excipient, uses of the modified natural killer cells, and methods for identifying depleted natural killer cells and culturing the modified natural killer cells are provided.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: February 5, 2019
    Assignee: Academia Sinica
    Inventors: Nan-Shih Liao, Jan-Mou Lee
  • Patent number: 10172885
    Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: January 8, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Martin Pulé, Khai Kong, Shaun Cordoba
  • Patent number: 10166257
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 1, 2019
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10130659
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: November 20, 2018
    Assignee: IOVANCE BIOTHERAPEUTICS, INC.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10059743
    Abstract: The present invention relates to a peptide derivative for regulating the thymic stromal lymphoid protein-mediated signaling and a pharmaceutical composition including the peptide derivative for preventing and treating allergy and asthma diseases and, more particularly, to a peptide derivative represented by Chemical Formula 1 and a pharmaceutical composition including the peptide derivative for preventing and treating allergy and asthma diseases. According to the present invention, provided are a peptide derivative capable of effectively inhibiting the formation of an inflammatory response of allergy and asthma diseases and a pharmaceutical composition including the peptide derivative. By using the present invention, various allergy and asthma diseases can be fundamentally prevented or treated.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: August 28, 2018
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS
    Inventors: Youngjoo Byun, Ki Yong Lee, Kiho Lee, Young Ho Jeon, Yong Woo Jung
  • Patent number: 9993502
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9975959
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: May 22, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, Nicholas Marshall, John Blazeck, Wei-Cheng Lu
  • Patent number: 9969975
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 15, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9957291
    Abstract: Protected fluorescent reagent compounds and their methods of synthesis are provided. The compounds are useful in various fluorescence-based analytical methods, including the analysis of highly multiplexed optical reactions in large numbers at high densities, such as single molecule real time nucleic acid sequencing reactions. The compounds contain fluorescent dye elements, that allow the compounds to be detected with high sensitivity at desirable wavelengths, binding elements, that allow the compounds to be recognized specifically by target biomolecules, and protective shield elements, that decrease undesirable contacts between the fluorescent dye elements and the bound target biomolecules and that therefore decrease photodamage of the bound target biomolecules by the fluorescent dye elements.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: May 1, 2018
    Assignee: Pacific Biosciences of California, Inc.
    Inventors: Lubomir Sebo, Jeremiah Hanes, Gene Shen, Louis Brogley, Stephen Yue, Frank Zheng, Yuri Lapin, John Lyle, Honey Osuna, Andrei Fedorov
  • Patent number: 9950011
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9950010
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Patent number: 9889160
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 13, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • Patent number: 9889161
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 13, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • Patent number: 9844569
    Abstract: Methods of obtaining a cell population enriched for tumor-reactive T cells, the method comprising: (a) obtaining a bulk population of peripheral blood mononuclear cells (PBMCs) from a sample of peripheral blood; (b) specifically selecting CD8+T cells that also express PD-1 and/or TIM-3 from the bulk population; and (c) separating the cells selected in (b) from unselected cells to obtain a cell population enriched for tumor-reactive T cells are disclosed. Related methods of administering a cell population enriched for tumor-reactive T cells to a mammal, methods of obtaining a pharmaceutical composition comprising a cell population enriched for tumor-reactive T cells, and isolated or purified cell populations are also disclosed.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: December 19, 2017
    Assignee: The United State of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Alena Gros, Steven A. Rosenberg
  • Patent number: 9809797
    Abstract: A method of carrying out adoptive immunotherapy by administering a subject an antigen-specific cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount is described. In the method, the CTL preparation is preferably administered as a preparation of an in vitro antigen-stimulated and expanded primate CTL population, the CTL population: (i) depleted of FoxP3+ T lymphocytes prior to antigen stimulation; (ii) antigen-stimulated in vitro in the presence of interleukin-21; or (iii) both depleted of FoxP3+ T lymphocytes prior to antigen stimulation and then antigen-stimulated in vitro in the presence of interleukin-21. Methods of preparing such compositions, and compositions useful for carrying out the adoptive immunotherapy, are also described.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: November 7, 2017
    Assignee: NATIONAL INSTITUTES OF HEALTH (NIH) U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS) DIVISION OF EXTRAMURAL INVENTIONS AND TECHNOLOGY
    Inventors: Cassian Yee, Yongqing Li
  • Patent number: 9808505
    Abstract: The influence of TF, endothelial cell protein C receptor (EPCR) and protease activated receptor-1 (PAR1) on tumor growth of malignant pleural mesothelioma (MPM) is disclosed. MPM cells that lack or express TF, EPCR or PAR1 and a murine orthotopic model of MPM led to the discovery that intrapleural administration into nude mice of REN MPM cells expressing TF and PAR1 but lacking EPCR and PAR2 generated large pleural cavity tumors. Suppression of TF or PAR1 expression markedly reduced tumor growth. Overexpression of TF in non-aggressive MPM cells expressing EPCR and PAR1 but exhibiting minimal levels of TF failed to alter their tumorigenicity. Introduction of EPCR expression in aggressive MPM cells attenuated tumor growth whereas EPCR silencing in non-aggressive MPM cells overexpressing TF increased tumorigenicity of non-aggressive cells. Expression of EPCR by MPM cells suppresses tumor growth and treats MPM.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 7, 2017
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Usha R. Pendurthi, Vijaya M. R. Lella, Shivakeshava Gaddam, Steven Idell
  • Patent number: 9763983
    Abstract: Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: September 19, 2017
    Assignee: ANTHROGENESIS CORPORATION
    Inventors: Xiaokui Zhang, Robert J. Hariri, Vanessa Voskinarian-Berse, Lin Kang, Eric Law, Stewart Abbot
  • Patent number: 9745552
    Abstract: The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: August 29, 2017
    Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
    Inventors: Stephan Fricke, Frank Emmrich, Nadja Hilger
  • Patent number: 9597356
    Abstract: The present invention discloses a use of dendritic killer cell population for manufacturing medication. The dendritic killer cell population is generated by culturing peripheral blood mononuclear cells with effective amounts of various cytokines for an appropriate time period, and the conserved cytokine is IL-15. Meanwhile a pharmaceutical composition comprises the above dendritic killer cell population for treating cancers is also disclosed in the present invention.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: March 21, 2017
    Assignee: FULLHOPE BIOMEDICAL CO., LTD
    Inventor: Jan Mou Lee
  • Patent number: 9504717
    Abstract: Methods and compositions are provided for combined transplantation of a solid organ and hematopoietic cells to an HLA mismatched recipient, where tolerance to the graft is established through development of a persistent mixed chimerism. An individual with persistent mixed chimerism, usually for a period of at least six months, is able to withdraw from the use of immunosuppressive drugs after a period of time sufficient to establish tolerance.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: November 29, 2016
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Samuel Strober, Robert Lowsky
  • Patent number: 9422351
    Abstract: The present invention relates to B7-H4-specific chimeric antigen receptor compositions and methods of use thereof.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: August 23, 2016
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Nathalie Scholler, Denarda Dangaj, Aizhi Zhao, Daniel J. Powell
  • Patent number: 9404083
    Abstract: A technique is needed which can amplify NK cells in vitro and prepare optimum number of NK cells for the adoptive immunotherapy. A method for amplifying NK cells is provided which comprises steps of: preparing cell population which is comprised of NK cells, removing T cells from the cell population which is comprised of NK cells, and, after removal of T cells, cultivating the remaining cells in a medium supplemented with 2500 to 2831 IU/mL of IL-2. The method for amplifying NK cells of the present invention may comprise a step of removing hematopoietic progenitor cells from the cell population. The present invention provides a pharmaceutical composition for adoptive immunotherapy, comprising NK cells which are prepared by the amplifying method of the present invention.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: August 2, 2016
    Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, TELLA, INC.
    Inventors: Yoshikazu Yonemitsu, Yui Harada, Satoru Saito, Yuichiro Yazaki, Masato Okamoto, Takefumi Ishidao
  • Patent number: 9394517
    Abstract: The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: July 19, 2016
    Assignee: IMCYSE SA
    Inventor: Jean-Marie Saint-Remy
  • Patent number: 9376482
    Abstract: The present invention relates to a method for producing a cell line expressing a stabilized functional single chain-antigen-recognizing genetic construct (scARC), comprising a genetic construct of the human scARC to be expressed, comprising the domains huV1/2—Li-huV2/1—C4/3 and a genetic construct comprising the corresponding hetero-/(homo-)dimeric domain C3/4, containing xenogenic, in its special case murine amino acid exchanges in the domains C4/3 and C3/4, wherein co-expression of the genetic constructs of the scARC-fragments occurs through the cell. Preferably, the scARCs are single chain-TCRs (scTCRs) or antibody-scFv-fragments, which further preferably recognize tumor associated peptide antigens (TAA). The present invention further relates to a gp100-protein-specific T-cell response mediated ?/? T-cell receptor rationally mutated by means of the method of the present invention and its uses.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: June 28, 2016
    Assignee: Johannes Gutenberg-Universität Mainz
    Inventors: Ralf-Holger Voss, Matthias Theobald, Ratna Sari Intan Pöndl, Renate Engel, Simone Thomas
  • Patent number: 9376663
    Abstract: The present invention is directed to in vitro methods for promoting expression of G-protein coupled receptor 15 (GPR15) on T cells, GPR15+ enriched populations of T cells generated using these methods and compositions thereof, as well as methods of using these T cell populations for therapeutic purposes.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: June 28, 2016
    Assignee: New York University
    Inventors: Dan R. Littman, Sang-Won Kim
  • Patent number: 9328171
    Abstract: [Problem] To provide an anti-human TSLP receptor antibody that specifically binds to human TSLP receptor and inhibits an action of human TSLP through human TSLP receptor. [Means for Solution] An anti-human TSLP receptor antibody had been studied by the present inventors, and an anti-human TSLP receptor antibody comprising a heavy chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 118 of SEQ ID NO: 1 and a light chain variable region consisting of the amino acid sequence of amino acid numbers 1 to 108 of SEQ ID NO: 3 was provided. It was revealed that the anti-human TSLP receptor antibody inhibits expression of TARC mRNA induced by TSLP and production of MDC proteins, and suppressed an allergic reaction in a monkey Ascaris antigen sensitization model, and then the present invention was completed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: May 3, 2016
    Assignee: Astellas Pharma Inc.
    Inventors: Hiromu Sato, Daisuke Yamajuku, Kazunori Arai, Mako Ogino
  • Patent number: 9290736
    Abstract: A method of generating a CD4+FoxP3+ Treg cell, the method includes administering at least one complement antagonist to a naive CD4+ T cell at an amount effective to substantially inhibits C3a receptor (C3aR) and/or C5a receptor (C5aR) signal transduction in the CD4+ T cell, induce TGF-?1 expression of the CD4+ T cell, and induce differentiation of the of the naive CD4+ T cell into a CD4+FoxP3+ Treg cell.
    Type: Grant
    Filed: November 4, 2010
    Date of Patent: March 22, 2016
    Assignee: Case Western Reserve University
    Inventors: M. Edward Medof, Feng Lin, Michael G. Strainic
  • Patent number: 9289452
    Abstract: Embodiments of the present invention provides bone graft compositions, and methods for their use and manufacture. A bone graft composition may include a first amount of non-demineralized cancellous bone. The composition may further include a second amount of demineralized cancellous bone. The composition may also include a third amount of demineralized cortical bone. The non-demineralized cancellous bone, the demineralized cancellous bone, and the demineralized cortical bone may be obtained from the same cadaveric donor.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: March 22, 2016
    Assignee: AlloSource
    Inventor: Yaling Shi
  • Patent number: 9265795
    Abstract: The present invention provides a therapeutic composition comprising: (i) Trolox, Na+, K+, Ca2+, Mg2+, Cl?, H2PO4?, HEPES, lactobionate, sucrose, mannitol, glucose, dextran-40, adenosine, glutathione; and (ii) stem cells or progenitor cells, wherein the composition does not comprise a dipolar aprotic solvent, in particular DMSO. The present invention also relates to methods of formulating said composition for cryopreservation and subsequent direct administration to a patient, and medicaments comprising said composition.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: February 23, 2016
    Assignee: RENEURON LIMITED
    Inventors: Andrew Hope, Erik Miljan, John Sinden
  • Patent number: 9265822
    Abstract: The present invention provides compositions and methods for generation of an anti-influenza immune response. In particular, conserved T cell epitopes within matrix protein and nucleoprotein components of influenza virus have been identified and further screened for those structures that will bind either or both of HLA I and II molecules. Methods for vaccinating subjects with formulations of such peptides for the treatment or prevention of influenza infaction also are described.
    Type: Grant
    Filed: September 30, 2010
    Date of Patent: February 23, 2016
    Assignee: Saint Louis University
    Inventor: Daniel Hoft
  • Patent number: 9260696
    Abstract: A method for producing NK cells from pluripotent stem cells, which includes culturing pluripotent stem cells in a first serum-free medium, aggregating the undifferentiated stem cells to form embryoid bodies, which are cultured to produce hematopoietic precursor cells, and culturing the precursor cells in a serum-free medium to produce the NK cells. Methods for using such NK cells, e.g., in the treatment of cancer and infectious disease are also provided.
    Type: Grant
    Filed: April 23, 2013
    Date of Patent: February 16, 2016
    Inventors: Dan S. Kaufman, David A. Knorr
  • Publication number: 20150147304
    Abstract: The invention relates to a method of inducing Foxp3 expression in a T cell comprising (i) stimulating a T cell (ii) inhibiting signalling via PI3K alpha or PI3K delta or m-TOR or Akt in said T cell, wherein said inhibition is commenced 10 to 22 hours after the stimulation of (i). The invention also relates to certain uses of PI3K inhibitors, PI3K inhibitors for particular uses, and kits.
    Type: Application
    Filed: October 29, 2014
    Publication date: May 28, 2015
    Inventor: Matthias Michael Merkenschlager
  • Publication number: 20150139971
    Abstract: An object of the present invention is to establish a method that enables safe and convenient large-scale preparation of regulatory dendritic cells. The present invention provides a method for preparing regulatory dendritic cells, which comprises culturing cells that can be induced to result in regulatory dendritic cells in the presence of a [1,2,4]triazolo[1,5-a]pyrimidine derivative.
    Type: Application
    Filed: January 28, 2015
    Publication date: May 21, 2015
    Applicants: NIPPON KAYAKU KABUSHIKI KAISHA, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
    Inventors: Satoru TODO, Kenichiro YAMASHITA, Susumu SHIBASAKI
  • Publication number: 20150139943
    Abstract: Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8?); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3?). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.
    Type: Application
    Filed: October 17, 2014
    Publication date: May 21, 2015
    Applicants: National University of Singapore, St. Jude Children's Research Hospital
    Inventors: Dario Campana, Ko Kudo
  • Publication number: 20150139904
    Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.
    Type: Application
    Filed: May 21, 2013
    Publication date: May 21, 2015
    Applicant: University of Miami
    Inventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Liu Zhao-Jun, Sapna Deo
  • Publication number: 20150139946
    Abstract: Provided is a method for monitoring a gene mutation associated with a cancer in a patient over time. Also provided is a method of selecting and/or applying treatment or therapy for a subject.
    Type: Application
    Filed: October 19, 2014
    Publication date: May 21, 2015
    Inventors: Mark G. Erlander, Karena Kosco, Cecile Rose Vibat
  • Publication number: 20150140041
    Abstract: Cancer antigens containing mutations in an expressed gene of cancer cells from a cancer patient are identified. Sequences from cancer cells obtained using a parallel sequencing platform are selected by comparing to the patient's normal genes or to normal genes from an HLA-matched individual. Sequences are further selected by identifying an HLA supertype of the cancer patient and selecting for that HLA supertype, sequences that have a particular amino acid at the mutant position and/or corresponding wild-type position in the effected gene. Peptides containing cancer antigens (i.e., mutations—once a mutation is defined, what makes it an immunogen is its ability to induce an immune response) are optionally tested for binding to HLA antigens of the cancer patient. Peptides containing the cancer antigens are evaluated for activating T cells (e.g., helper T lymphocytes and cytotoxic T lymphocytes (CTL)) cell lines from the cancer patient or from an HLA-matched donor.
    Type: Application
    Filed: January 12, 2015
    Publication date: May 21, 2015
    Inventor: Maria Antonia VITIELLO
  • Patent number: 9034317
    Abstract: This invention pertains to cancer immunotherapy, by providing a proinflammatory dendritic cell (DC), which has been stimulated to maturation ex vivo by specific treatment, a method for such treatment and a composition comprising the proinflammatory DC. The DC may be used as a cell based immunotherapy for inhibiting tumor cell proliferation.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: May 19, 2015
    Assignee: IMMUNICUM AB
    Inventors: Alex Karlsson-Parra, Bengt Andersson, AnnaCarin Wallgren
  • Publication number: 20150132290
    Abstract: The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 14, 2015
    Inventors: Ephraim Joseph Fuchs, Heather Jills Symons, Lode Swinnen
  • Publication number: 20150132272
    Abstract: The invention is based upon the discovery that T regulatory type 1 (Tr1) cells express particular cell surface markers that allow for their selection, enrichment, isolation, purification and administration. The ability to use the particular markers described herein to select, enrich, isolate, purity and administer Tr1 cells allows for improved methods of Tr1 therapies for treating a wide variety of diseases and disorders.
    Type: Application
    Filed: June 18, 2013
    Publication date: May 14, 2015
    Inventors: Richard A. Flavell, Nicola Gagliani, Silvia Gregori, Samuel Huber, Chiara Francesca Magnani, Maria Grazia Roncarolo
  • Publication number: 20150132329
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Application
    Filed: May 22, 2012
    Publication date: May 14, 2015
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Patent number: 9028812
    Abstract: The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.
    Type: Grant
    Filed: October 29, 2010
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Dartmouth College
    Inventor: Charles L. Sentman
  • Publication number: 20150125478
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: December 5, 2014
    Publication date: May 7, 2015
    Inventors: Toni WEINSCHENK, Oliver SCHOOR, Claudia TRAUTWEIN, Norbert HILF, Steffan WALTER, Harpreet SINGH
  • Publication number: 20150118208
    Abstract: The present disclosure provides methods for generating enhanced affinity T cell receptors by agonist selection of hematopoietic progenitor cells expressing an antigen specific TCR? cultured with stromal cells expressing Delta-like-1 or Delta-like-4, compositions prepared from such methods, and uses of thereof.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 30, 2015
    Inventors: Thomas M. Schmitt, Philip D. Greenberg
  • Publication number: 20150118206
    Abstract: Methods are provided for treating, mitigating or protecting from radiation-induced injury using bone marrow stromal cells expanded in culture, adipose-tissue derived non-adherent stromal cells, or the culture supernatant thereof.
    Type: Application
    Filed: July 10, 2012
    Publication date: April 30, 2015
    Inventors: Chandan Guha, Subhrajit Saha, Alan Alfieri, Payel Bhanja
  • Publication number: 20150118207
    Abstract: The present invention relates to a method for producing natural killer cells (hereinafter, referred to as “NK cells”), NK cells produced thereby, and a composition for treating cancers and infectious diseases containing the same. The present invention provides a method for producing NK cells, which maintain high cytotoxicity and cell viability to exhibit high therapeutic effects against cancers and infectious diseases and can be cultured ex vivo at high efficiency and high concentration. In addition, a culture method which maintains cell concentration at a constant level is used for the production of NK cells, and thus the overgrowth of the cells can be prevented so that the cells can be maintained at an optimal state. Particularly, even when the cells are thawed after freezing, the function of the cells is not impaired, and the NK cells can maintain high cell viability and cytotoxicity.
    Type: Application
    Filed: December 18, 2012
    Publication date: April 30, 2015
    Applicants: Mogam Biotechnology Institute, Green Cross Labcell
    Inventors: Bokyung Min, Hana Choi, Okjae Lim, Jung Hyun Her, Sangmi Kang, Eun-Kyoung Lee, Hyejin Chung, Yu Kyeong Hwang
  • Publication number: 20150118209
    Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Inventors: John C. BYRD, Jason A. DUBOVSKY, Natarajan MUTHUSAMY, Amy Jo JOHNSON, David MIKLOS
  • Publication number: 20150110762
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a cell.
    Type: Application
    Filed: October 16, 2014
    Publication date: April 23, 2015
    Inventors: Michael C. Holmes, Jianbin Wang
  • Publication number: 20150110738
    Abstract: The present invention is directed to generating suppressor cells by treating naive T cells with a suppressor-inducing composition such as anti-CD3, anti-CD28, IL-2, TGF-?, or some combination thereof. Such suppressor cells are administered to patients to prevent or treat immune disorders and are allogeneic to the patient.
    Type: Application
    Filed: May 2, 2013
    Publication date: April 23, 2015
    Inventor: David Horwitz